570 related articles for article (PubMed ID: 32920239)
21. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection.
Martorana A; Gentile C; Lauria A
Viruses; 2020 Jul; 12(8):. PubMed ID: 32722574
[TBL] [Abstract][Full Text] [Related]
22. Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.
Ray AK; Sen Gupta PS; Panda SK; Biswal S; Bhattacharya U; Rana MK
Comput Biol Med; 2022 Mar; 142():105183. PubMed ID: 34986429
[TBL] [Abstract][Full Text] [Related]
23. Prediction of potential inhibitors of the dimeric SARS-CoV2 main proteinase through the MM/GBSA approach.
Bello M
J Mol Graph Model; 2020 Dec; 101():107762. PubMed ID: 33022569
[TBL] [Abstract][Full Text] [Related]
24. Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA.
Bello M; Martínez-Muñoz A; Balbuena-Rebolledo I
J Mol Model; 2020 Nov; 26(12):340. PubMed ID: 33184722
[TBL] [Abstract][Full Text] [Related]
25. Targeting the Main Protease of SARS-CoV-2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors.
Breidenbach J; Lemke C; Pillaiyar T; Schäkel L; Al Hamwi G; Diett M; Gedschold R; Geiger N; Lopez V; Mirza S; Namasivayam V; Schiedel AC; Sylvester K; Thimm D; Vielmuth C; Phuong Vu L; Zyulina M; Bodem J; Gütschow M; Müller CE
Angew Chem Int Ed Engl; 2021 Apr; 60(18):10423-10429. PubMed ID: 33655614
[TBL] [Abstract][Full Text] [Related]
26. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
Goyal B; Goyal D
ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
[TBL] [Abstract][Full Text] [Related]
27. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
28. Potential Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 606 Million Compounds.
Fischer A; Sellner M; Neranjan S; Smieško M; Lill MA
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32455534
[TBL] [Abstract][Full Text] [Related]
29. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
[TBL] [Abstract][Full Text] [Related]
30. Finding potent inhibitors against SARS-CoV-2 main protease through virtual screening, ADMET, and molecular dynamics simulation studies.
Roy R; Sk MF; Jonniya NA; Poddar S; Kar P
J Biomol Struct Dyn; 2022 Sep; 40(14):6556-6568. PubMed ID: 33682642
[TBL] [Abstract][Full Text] [Related]
31. Repurposing of FDA-approved drugs against active site and potential allosteric drug-binding sites of COVID-19 main protease.
Yuce M; Cicek E; Inan T; Dag AB; Kurkcuoglu O; Sungur FA
Proteins; 2021 Nov; 89(11):1425-1441. PubMed ID: 34169568
[TBL] [Abstract][Full Text] [Related]
32. A higher flexibility at the SARS-CoV-2 main protease active site compared to SARS-CoV and its potentialities for new inhibitor virtual screening targeting multi-conformers.
Rocha REO; Chaves EJF; Fischer PHC; Costa LSC; Grillo IB; da Cruz LEG; Guedes FC; da Silveira CH; Scotti MT; Camargo AD; Machado KS; Werhli AV; Ferreira RS; Rocha GB; de Lima LHF
J Biomol Struct Dyn; 2022; 40(19):9214-9234. PubMed ID: 33970798
[TBL] [Abstract][Full Text] [Related]
33. Computational Screening Using a Combination of Ligand-Based Machine Learning and Molecular Docking Methods for the Repurposing of Antivirals Targeting the SARS-CoV-2 Main Protease.
Yuda GPWC; Hanif N; Hermawan A
Daru; 2024 Jun; 32(1):47-65. PubMed ID: 37907683
[TBL] [Abstract][Full Text] [Related]
34. In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking.
Vázquez-Mendoza LH; Mendoza-Figueroa HL; García-Vázquez JB; Correa-Basurto J; García-Machorro J
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409348
[TBL] [Abstract][Full Text] [Related]
35. Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL
Jade D; Ayyamperumal S; Tallapaneni V; Joghee Nanjan CM; Barge S; Mohan S; Nanjan MJ
Eur J Pharmacol; 2021 Jun; 901():174082. PubMed ID: 33823185
[TBL] [Abstract][Full Text] [Related]
36. Investigation of Some Antiviral
Hagar M; Ahmed HA; Aljohani G; Alhaddad OA
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486229
[TBL] [Abstract][Full Text] [Related]
37. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors.
Zhang L; Lin D; Sun X; Curth U; Drosten C; Sauerhering L; Becker S; Rox K; Hilgenfeld R
Science; 2020 Apr; 368(6489):409-412. PubMed ID: 32198291
[TBL] [Abstract][Full Text] [Related]
38. Structure-based virtual screening, in silico docking, ADME properties prediction and molecular dynamics studies for the identification of potential inhibitors against SARS-CoV-2 M
Mohan A; Rendine N; Mohammed MKS; Jeeva A; Ji HF; Talluri VR
Mol Divers; 2022 Jun; 26(3):1645-1661. PubMed ID: 34480682
[TBL] [Abstract][Full Text] [Related]
39. Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening.
Abian O; Ortega-Alarcon D; Jimenez-Alesanco A; Ceballos-Laita L; Vega S; Reyburn HT; Rizzuti B; Velazquez-Campoy A
Int J Biol Macromol; 2020 Dec; 164():1693-1703. PubMed ID: 32745548
[TBL] [Abstract][Full Text] [Related]
40. Biochemical and Computational Approach of Selected Phytocompounds from
Rakib A; Paul A; Chy MNU; Sami SA; Baral SK; Majumder M; Tareq AM; Amin MN; Shahriar A; Uddin MZ; Dutta M; Tallei TE; Emran TB; Simal-Gandara J
Molecules; 2020 Aug; 25(17):. PubMed ID: 32872217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
